(Q37147772)

18 August 2017

1 reference

title

Targeted therapy of cancer: new roles for pathologists--prostate cancer (English)

1 reference

18 August 2017

1 reference

Mark A Rubin

1

0 references

publication date

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

21 Suppl 2

1 reference

18 August 2017

S44-55

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2008.11

18 August 2017

0 references

cites work

Radical prostatectomy versus watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen receptor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Emergence of metastatic hormone-refractory disease in prostate cancer after anti-androgen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The androgen receptor gene mutations database (ARDB): 2004 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen receptor mutations in high-grade prostate cancer before hormonal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Activation of the human androgen receptor through a protein kinase A signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The biology of hormone refractory prostate cancer. Why does it develop?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Antisense therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Multiplex Biomarker Approach for Determining Risk of Prostate-Specific Antigen-Defined Recurrence of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

The role of metastasis-associated protein 1 in prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Defining aggressive prostate cancer using a 12-gene model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Confirmation of the high frequency of the TMPRSS2/ERG fusion gene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Platelet-Derived Growth Factor Receptor Inhibitor Imatinib Mesylate and Docetaxel: A Modular Phase I Trial in Androgen-Independent Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

Diversity of TMPRSS2-ERG fusion transcripts in the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

21 January 2018

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Effect of transforming growth factor-beta 1 on proliferation and death of rat prostatic cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Early castration-induced upregulation of transforming growth factor beta1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate-specific antigen in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Aneuploidy and rapid cell proliferation in recurrent prostate cancers with androgen receptor gene amplification

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Androgen receptor gene mutations in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Morphologic and immunohistochemical changes in prostate cancer after preoperative hormonal therapy. A comparative study of radical prostatectomies

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

Gene expression profiling predicts clinical outcome of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.11

7 January 2021

10.1038/MODPATHOL.2008.11

Identifiers

DOI

1 reference

PubMed ID

18437173

Dimensions Publication ID

18 August 2017

0 references

1 reference

PubMed ID

18437173